Real-world Data to Generate Evidence About Healthcare InterventionsThe Application of an Ethics Framework for Big Data in Health and Research

被引:0
作者
Wendy Lipworth
机构
[1] The University of Sydney,Sydney Health Ethics, Faculty of Medicine and Health
来源
Asian Bioethics Review | 2019年 / 11卷
关键词
Big Data; Real-world evidence; Registries; Conflict of interest; Integrity;
D O I
暂无
中图分类号
学科分类号
摘要
It is increasingly recognised that evidence generated using “real-world data” (RWD) is crucial for assessing the safety and effectiveness of health-related interventions. This, however, raises a number of issues, including those related to (1) the quality of RWD, and of the scientific methods used to generate evidence from it, and (2) the potential for those gathering and using RWD be driven by commercial, political, professional or personal self-interest. This article is an application of the framework presented in this issue of ABR (Xafis et al. 2019). Please refer to that article for more information on how this framework is to be used, including a full explanation of the key values involved and the balancing approach used in the case study at the end to demonstrate how those generating or using RWD can make use of values when deliberating about ethical issues.
引用
收藏
页码:289 / 298
页数:9
相关论文
共 22 条
[1]  
Coloma PM(2013)Postmarketing safety surveillance: where does signal detection using electronic healthcare records fit into the big picture? Drug Safety 36 183-197
[2]  
Trifirò G(2014)Oversight and evidence in stem cell innovation: an examination of international guidelines Law, Innovation and Technology 6 30-50
[3]  
Patadia V(2015)Conflicting results between randomized trials and observational studies on the impact of proton pump inhibitors on cardiovascular events when coadministered with dual antiplatelet therapy: systematic review Circulation Cardiovascular Quality and Outcomes 8 47-55
[4]  
Sturkenboom M(2014)Review of the quality of observational studies of the association between rosiglitazone and acute myocardial infarction Journal of Population Therapeutics and Clinical Pharmacology 21 e214-e232
[5]  
Lysaght T(2018)Vaginal mesh procedures need compulsory register, says royal college BMJ 360 k586-846
[6]  
Melloni C(2007)The rosiglitazone story—lessons from an FDA Advisory Committee meeting New England Journal of Medicine 357 844-806
[7]  
Washam JB(2010)Revisiting the rosiglitazone story—lessons learned New England Journal of Medicine 363 803-227
[8]  
Jones WS(2015)Was there really any evidence that rosiglitazone increased the risk of myocardial infarction or death from cardiovascular causes? Pharmacoepidemiology and Drug Safety 24 223-undefined
[9]  
Halim SA(2018)Government’s vaginal mesh audit does not go far enough, say campaigners BMJ 361 k1701-undefined
[10]  
Hasselblad V(undefined)undefined undefined undefined undefined-undefined